. Author manuscript; available in PMC: 2019 Aug 15.

Published in final edited form as: Am J Cardiol. 2018 May 15;122(4):597–603. doi: 10.1016/j.amjcard.2018.04.049

Table 2.

Risk of outcomes by CHA2DS2-VASc score and renal impairment.^*

Outcome Evaluated Variable	Hazard Ratio	95% CI		P-value
Outcome Evaluated Variable	Hazard Ratio	Lower	Upper	P-value
Death
CHA2DS2-VASc 2–5	5.16	2.65	10.06	<.0001

CHA2DS2-VASc 6–9	11.26	5.75	22.05	<.0001
Renal Impairment	2.06	1.64	2.60	<.0001
Baseline Anticoagulation	0.76	0.53	1.09	0.13

Thromboembolic Events
CHA2DS2-VASc 2–5	3.52	1.64	7.56	0.001
CHA2DS2-VASc 6–9	9.26	4.29	19.99	<.0001
Renal Impairment	1.34	0.96	1.87	0.08
Baseline Anticoagulation	1.89	1.33	2.69	0.0004

Atrial Fibrillation
CHA2DS2-VASc 2–5	1.59	1.09	2.32	0.02
CHA2DS2-VASc 6–9	2.40	1.61	3.57	<.0001
Renal Impairment	1.31	0.98	1.74	0.07
Baseline Anticoagulation	1.29	0.93	1.78	0.12

CKD stage 3 or greater defined by ICD-9 codes.